Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

GlobeNewswire May 12, 2021

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire May 11, 2021

Algernon Pharmaceuticals (CSE:AGN) files end of Phase 2 meeting request with U.S. FDA

Brieanna McCutcheon  April 26, 2021

Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

GlobeNewswire April 26, 2021

Algernon Pharmaceuticals (CSE:AGN) to file End-of-Phase 2 meeting request with U.S. FDA

Brieanna McCutcheon  April 8, 2021

Algernon Working to Meet with FDA on Possible Phase 3 COVID-19 Trial

Stockhouse Editorial April 8, 2021

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

GlobeNewswire April 8, 2021

Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

GlobeNewswire April 6, 2021

Algernon Pharmaceuticals (CSE:AGN) reports on latest phase of its Ifenprodil COVID-19 trial

Trevor Abes  March 31, 2021

Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

GlobeNewswire March 31, 2021

Algernon Joins the First Psychedelic Stock Index ETF on the Market

Stockhouse Editorial March 29, 2021

Algernon Pharmaceuticals (CSE:AGN) added to the Horizons Psychedelic Stock Index ETF

John Ballem  March 29, 2021

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

GlobeNewswire March 29, 2021

Algernon (CSE:AGN) submits FDA meeting request for DMT clinical research program

Trevor Abes  March 17, 2021

Algernon Requests Psychedelic Drug Clinical Research Program for Stroke from FDA

Stockhouse Editorial March 17, 2021

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

GlobeNewswire March 17, 2021

Algernon Pharmaceuticals (CSE:AGN) provides update on Phase 2b/3 COVID-19 trial of Ifenprodil

Brieanna McCutcheon  March 11, 2021

Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

GlobeNewswire March 11, 2021

Algernon Pharmaceuticals Announces Increase and Close of Private Placement

GlobeNewswire March 5, 2021

Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

GlobeNewswire March 3, 2021